TABLE 1.
Baseline patient characteristics
| Age at diagnosis, median (range) | 69 (31‐88) |
| Gender, N (%) | |
| Female | 10 (41.7) |
| Male | 14 (58.3) |
| Race/Ethnicity, N (%) | |
| Hispanic | 11 (41.8) |
| White | 6 (25.0) |
| Asian | 4 (16.7) |
| Black | 3 (12.5) |
| Hematologic malignancy, N (%) | 14 (58.3) |
| Non‐Hodgkin lymphoma | 5 (20.8) |
| Multiple myeloma | 4 (16.7) |
| Acute lymphoblastic leukemia | 2 (8.3) |
| Hodgkin lymphoma | 1 (4.2) |
| Myelofibrosis | 1 (4.2) |
| Chronic lymphocytic leukemia | 1 (4.2) |
| Solid malignancy, N (%) | 10 (41.7) |
| Colorectal | 2 (8.3) |
| Breast | 2 (8.3) |
| Endometrial | 2 (8.3) |
| Prostate | 1 (4.2) |
| Lung | 1 (4.2) |
| Ovarian | 1 (4.2) |
| Laryngeal | 1 (4.2) |
| Stage of solid tumor, N (%) | |
| I | 3 (30.0) |
| II | 3 (30.0) |
| III | 4 (40.0) |
| Active disease, N (%) | 17 (70.8) |
| Receiving cancer‐directed treatment at time of convalescent plasma, N (%) | 11 (45.8) |
| Targeted therapy | 9 (37.5) |
| Systemic chemotherapy | 6 (25.0) |
| Radiation therapy | 1 (4.2) |
| Immunomodulator | 2 (8.3) |
| Intrathecal chemotherapy | 1 (4.2) |
| Time from cancer diagnosis to convalescent plasma in months, median (range) | 42.1 (2.3‐274.9) |